By Chloé Nefdt, Professional Nurse & Founder of IVgo
You know the one. The injury that just... lingers. You rested it, you iced it, you did your physio exercises with the enthusiasm of someone flossing the day before a dentist appointment. And yet here you are, four months later, still wincing when you reach for the top shelf or pretending that particular hiking trail "isn't really your thing anymore."
If this sounds familiar, you've probably already Googled your way to BPC-157. Maybe you even read my guide to BPC-157 in South Africa. And somewhere in that research, you encountered a name that sounds like it was invented by a Marvel screenwriter: the Wolverine Stack.
The name is ridiculous. The science behind it is not. Let me walk you through exactly what the Wolverine Stack is, what the research actually says, and how I administer it at IVgo - because there's a significant gap between what peptide forums promise and what the evidence supports. I'd rather you sit on the evidence side.
What Is the Wolverine Stack?
The Wolverine Stack is the combination of two peptides - BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4) - used together to support tissue healing and recovery. The nickname comes from the X-Men character's superhuman regeneration, which is both a great marketing hook and a wildly irresponsible comparison. Nobody is regrowing limbs here. What the combination does offer is two distinct healing mechanisms working in parallel - and that's genuinely interesting from a clinical perspective.
BPC-157 has been the subject of over 100 peer-reviewed papers, primarily from Professor Predrag Sikiric's team at the University of Zagreb. TB-500 has its own substantial body of research, anchored by foundational work from Allan Goldstein and colleagues. Together, they represent two of the most studied peptides in the regenerative medicine space.
But let me be honest from the start: the vast majority of this research is preclinical - meaning animal models. A 2025 systematic review by Vasireddi et al. in the American Journal of Sports Medicine analysed 36 studies on BPC-157 and found 35 were preclinical, with only one small clinical retrospective. TB-500 has even less human data. The results are promising. The evidence base is still maturing. You deserve to know both of those things.
How BPC-157 Works (The Quick Version)
I covered BPC-157 in detail in my complete South African guide, so I'll keep this brief.
BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. Its primary mechanisms include:
- Angiogenesis - promoting new blood vessel formation at injury sites (which is critical for tendons and ligaments that have poor blood supply to begin with)
- Nitric oxide pathway modulation - regulating inflammation rather than simply suppressing it
- Growth hormone receptor upregulation - enhancing the tissue's response to your body's own growth signals
- Fibroblast stimulation - accelerating the cells responsible for collagen production and tissue structural repair
Research by Chang et al. (2011, Journal of Orthopaedic Research) demonstrated BPC-157's ability to promote tendon-to-bone healing, while Staresinic et al. (2006, Journal of Physiology and Pharmacology) showed significant improvements in transected muscle healing. If you want the deep dive with all the citations, the BPC-157 post has you covered.
How TB-500 Works (The New Information)
TB-500 is where this post earns its keep. If BPC-157 is the peptide you've already heard about, TB-500 is the one that deserves equal attention - and considerably more explanation.
TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide that occurs naturally in nearly all human cells. It's not some exotic laboratory creation - your body is already producing Thymosin Beta-4. It's found at particularly high concentrations in wound fluid, blood platelets, and white blood cells. When you cut your finger or tear a muscle fibre, Tβ4 is one of the first molecules your body deploys to the scene.
The landmark study here is Bock-Marquette et al. (2004), published in Nature - which, for context, is about as prestigious as scientific journals get. They demonstrated that Thymosin Beta-4 activates integrin-linked kinase (ILK), promotes cardiac cell migration and survival, and significantly improved cardiac function after coronary artery ligation in mice. This wasn't a supplement company's white paper - it was Nature.
TB-500's Key Mechanisms
Actin regulation. This is TB-500's signature move. It binds to and sequesters G-actin monomers - the building blocks of the cell's structural skeleton - maintaining a pool of actin ready for rapid deployment. When cells need to migrate to an injury site, TB-500 ensures they have the structural machinery to get there. Think of it as keeping a fleet of emergency vehicles fuelled and ready rather than waiting for someone to find the keys.
Cell migration. By regulating actin polymerisation, TB-500 promotes the migration of endothelial cells, keratinocytes, and other cell types critical for tissue repair. Sosne et al. (2007, Clinical Ophthalmology) demonstrated this in corneal wound healing models, where Thymosin Beta-4 significantly accelerated repair through enhanced cell migration.
Anti-inflammatory signalling. TB-500 demonstrates potent inhibitory effects on NF-κB signalling - the master switch of inflammatory gene expression. By blocking nuclear translocation of the RelA/p65 protein, it reduces transcription of pro-inflammatory cytokines. In practical terms: it helps dial down the excessive inflammation that often stalls healing in chronic injuries.
Stem cell mobilisation. Perhaps most intriguingly, research has shown that Thymosin Beta-4 can mobilise and recruit endogenous stem and progenitor cells - coaxing them from their resident niches to sites of damage. Kleinman and Sosne (2016, Vitamins and Hormones) reviewed this mechanism in dermal healing models.
Cell survival (anti-apoptotic). TB-500 activates the Akt survival pathway through ILK, reducing programmed cell death at injury sites. More surviving cells at the wound means more raw material for repair.
The overall picture: TB-500 works systemically. Where BPC-157 tends to exert its strongest effects locally at or near the site of injury, TB-500 enhances your body's healing infrastructure across multiple tissue types simultaneously.
Why They're Combined: The Synergy Explained
Here's where it gets interesting. BPC-157 and TB-500 aren't just two healing peptides thrown together because more must be better. They address different rate-limiting steps in the repair process.
BPC-157 excels at:
- Increasing blood supply to the injury (angiogenesis)
- Modulating the inflammatory response
- Stimulating local tissue repair at the injury site
- Upregulating growth factor receptor expression
TB-500 excels at:
- Mobilising cells to the injury site (migration)
- Providing structural building materials (actin regulation)
- Recruiting stem and progenitor cells
- Reducing systemic inflammation via NF-κB inhibition
- Promoting cell survival at damaged tissue
Think of healing as a construction project. BPC-157 builds the roads to the site and manages the building inspectors. TB-500 sends in the workers, the materials, and the architects. Neither one does the whole job as effectively alone.
This is a genuine complementary mechanism - they're working through different biological pathways to support different phases of tissue repair. The inflammatory phase, the proliferative phase, and the remodelling phase each benefit from different aspects of this combination.
Is there a randomised controlled trial proving the combination is superior to either peptide alone in humans? No. I won't pretend there is. But the mechanistic rationale is sound, the preclinical evidence for each peptide individually is substantial, and the clinical observations from practitioners using the combination are consistently positive. That's where the evidence sits today.
Who Is the Wolverine Stack For?
Based on the research and my clinical experience at IVgo, the Wolverine Stack is most commonly sought by:
Athletes and Serious Trainers
Whether it's a rotator cuff that's been grumbling for months, a hamstring that re-tears every time you return to sprinting, or chronic tendinopathy from repetitive training loads. Athletes are drawn to the Wolverine Stack because persistent soft tissue injuries are the tax you pay for pushing your body - and conventional recovery often isn't fast enough. (Important WADA caveat below - read it.)
Post-Surgical Recovery
If you've had orthopaedic surgery - ACL reconstruction, rotator cuff repair, meniscus surgery - the healing timeline is often measured in months. Clients come to IVgo looking to support that process, particularly when they feel their recovery has plateaued.
Chronic Injuries That Won't Resolve
The Achilles tendon that's been "almost better" for a year. The tennis elbow that physio improved but never fully fixed. The low back issue that flares every time you think you've beaten it. Chronic injuries often involve compromised blood supply and persistent low-grade inflammation - exactly the conditions both BPC-157 and TB-500 are researched for.
Weekend Warriors and Active Professionals
You don't need to be a competitive athlete to benefit. I see plenty of clients who surf, cycle, run, do CrossFit, or play social sports - people whose injuries don't warrant surgery but significantly impact their quality of life. The guy who can't pick up his toddler without his shoulder catching. The runner who had to downgrade from trail running to "brisk walking." That person.
What to Expect: Protocol, Timeline, and Results
I'm going to be realistic here, because overpromising is the single biggest problem in the peptide space.
The Protocol
At IVgo, the Wolverine Stack comes as a combined pre-loaded pen device - both BPC-157 and TB-500 in one pen, administered via subcutaneous injection (a small, shallow injection just under the skin, similar to an insulin pen). No vials, no mixing, no reconstitution. The pen is designed for self-administration after I've trained you on technique during your first session.
Each pen provides two 6-week treatment cycles. Most clients complete one full cycle and reassess. Some proceed to a second cycle depending on the nature of their injury and their response.
Timeline
- Weeks 1-2: Most clients don't notice dramatic changes yet. Some report reduced inflammation or improved sleep. Others feel nothing. Both are normal.
- Weeks 3-4: This is typically when clients start reporting meaningful differences - reduced pain, improved range of motion, less stiffness. The "oh, I just noticed I reached for that without thinking" moment.
- Weeks 5-6: Continued improvement. This is where cumulative tissue remodelling becomes more apparent.
- Weeks 7-12 (second cycle, if used): Consolidation and further gains, particularly for more severe or chronic injuries.
What It Won't Do
It won't reattach a fully torn ligament. It won't reverse severe arthritis. It won't compensate for continuing to do the thing that caused the injury in the first place. If your physio told you to stop deadlifting heavy while your disc heals, BPC-157 and TB-500 aren't a cheat code to ignore that advice.
Peptides support healing. They don't replace the fundamentals: rest, rehabilitation, proper loading progression, and addressing root causes. Any provider who suggests otherwise is selling you a fantasy.
Safety and Side Effects
Let me split this into what the research shows and what I observe clinically.
What the Research Shows
BPC-157 has demonstrated a strong safety profile across published studies, with no significant toxic effects reported even at high doses in animal models. A recent pilot study involving two healthy adults who received intravenous BPC-157 infusions up to 20 mg was well tolerated, with no adverse events or clinically meaningful changes in vital signs, ECGs, or laboratory biomarkers.
TB-500 (Thymosin Beta-4) has been studied in human clinical trials - notably for dry eye syndrome and corneal wound healing - with a generally favourable safety profile. The cardiac studies by Bock-Marquette's group showed improved outcomes without reported toxicity in animal models.
What I See Clinically
The most common side effect is mild irritation at the injection site - redness, slight swelling, or tenderness. This typically resolves within hours. Some clients report mild fatigue or headache in the first few days, which tends to be transient.
Serious adverse events? In my practice, none. In the published literature at therapeutic doses, none that I'm aware of. But - and this is important - the absence of reported harm in limited studies is not the same as proven safety in large populations over long periods. This is exactly why I require a proper consultation and blood work reviewed by a doctor before starting anyone on a protocol. It's not bureaucracy. It's the responsible floor for peptide therapy.
WADA Status: What Athletes Need to Know
This section is non-negotiable reading if you compete in any sport with anti-doping oversight.
Both BPC-157 and TB-500 are prohibited by the World Anti-Doping Agency (WADA).
- BPC-157 falls under category S0 (Non-Approved Substances) - banned at all times, in and out of competition. Because it has no approved human therapeutic use, there is no pathway to a Therapeutic Use Exemption (TUE).
- TB-500 (Thymosin Beta-4 and its derivatives) is listed under S2 (Peptide Hormones, Growth Factors) - also banned at all times, in and out of competition.
This applies if you're subject to testing by WADA, SAIDS (South African Institute for Drug-Free Sport), or any affiliated anti-doping body. If you compete in rugby, athletics, cycling, swimming, CrossFit Games, triathlon, or any SAIDS-regulated sport at provincial level or above - the Wolverine Stack is off limits.
If you're a recreational athlete, gym-goer, or social sports player not subject to anti-doping testing, WADA regulations don't apply to you. But if there's even a possibility you might be tested, don't use it. The detection windows for peptides are evolving, and the consequences of a positive test are career-ending. This isn't worth a grey area.
How IVgo Administers the Wolverine Stack
IVgo is a mobile health service - I come to you. No clinic waiting rooms, no parking hassles, no rushing across Cape Town between appointments. Here's exactly how the process works:
1. Consultation. You book in with IVgo. I take a full health history, discuss your injury or recovery goals, and assess whether the Wolverine Stack is appropriate for your situation. Not everyone is a candidate, and I'd rather tell you that upfront than take your money for something that won't help you.
2. Blood work. I arrange blood work, which is reviewed by a doctor. This is non-negotiable. It's how we rule out contraindications, establish a baseline, and ensure you're a suitable candidate for peptide therapy.
3. Doctor review. A medical doctor reviews your results and signs off on the protocol. This isn't a rubber stamp - it's a genuine clinical checkpoint.
4. Pen delivery and training. Once cleared, I deliver your Wolverine Stack pen to your home. I demonstrate correct injection technique, walk you through the protocol, and make sure you're confident with self-administration before I leave. The pen is designed to make this straightforward - most clients are comfortable after one session.
5. Ongoing support. I'm available throughout your treatment for questions, check-ins, progress reviews, and protocol adjustments.
Pricing
| Treatment | What You Get | Price |
|---|---|---|
| BPC-157 Pen | Pre-loaded pen, two 6-week cycles | R3,000 |
| Wolverine Stack Pen | BPC-157 + TB-500 combined, pre-loaded pen, two 6-week cycles | R4,500 |
All peptides are sourced from registered South African compounding pharmacies. No imports of unknown origin, no mystery powders, no Telegram dealers. Every formulation is pharmaceutical-grade with verified purity and dosing.
IVgo also offers NAD+ therapy for clients interested in cellular health, energy, and longevity alongside their recovery protocols.
Frequently Asked Questions
Is the Wolverine Stack better than BPC-157 alone?
It depends on your situation. For straightforward, localised injuries - a single tendon issue, mild inflammation - BPC-157 alone may be entirely sufficient at R3,000. The Wolverine Stack adds value for more complex injuries, chronic conditions that haven't responded to BPC-157 alone, post-surgical recovery, or situations where multiple tissue types are involved. During your consultation, I'll give you an honest recommendation on which option makes sense for you. I'm not in the business of upselling - I'm in the business of outcomes.
How do I inject the pen myself?
The pre-loaded pen works like an insulin pen - you dial your dose, pinch a fold of skin (typically on your abdomen or thigh), insert the short needle at a slight angle, and press the plunger. It takes about 10 seconds. Most clients are mildly nervous before their first self-injection and mildly embarrassed about being nervous after they realise how simple it is. I train you in person and I'm a phone call away if anything feels off.
Can I use the Wolverine Stack alongside physiotherapy?
Absolutely - and I'd encourage it. Peptides support the biological healing process, but they don't replace rehabilitation, strengthening, or movement retraining. The best outcomes I've seen are in clients who combine the Wolverine Stack with a structured physio programme. Think of peptides as accelerating the biological healing while your physio ensures the structural and functional recovery is on track.
Are there any people who shouldn't use the Wolverine Stack?
Yes. Pregnant or breastfeeding women should not use peptide therapy. Individuals with active cancer or a history of cancer should discuss this with their oncologist - any compound that promotes cell growth and angiogenesis warrants caution in that context. People on blood thinners or with bleeding disorders should also be assessed carefully. This is precisely why the consultation and doctor review exist - to catch the situations where peptides aren't appropriate.
How long do I need to wait between cycles?
Each pen provides two 6-week cycles. After completing both cycles (12 weeks total), I recommend a minimum 30-day washout period before starting a new pen. This allows peptide receptors to remain responsive and prevents the diminished returns that can come with extended continuous use. We'll discuss the right approach for your specific situation during your treatment.
The Bottom Line
The Wolverine Stack - BPC-157 and TB-500 combined - represents one of the most compelling peptide protocols available for tissue recovery. The mechanistic rationale is strong: two peptides addressing different phases and pathways of healing, from blood vessel formation and inflammation modulation to cell migration and structural repair.
Is the evidence perfect? No. Most of it is preclinical, and we need more human trials. But the biological logic is sound, the individual evidence base for each peptide is substantial, and the clinical observations from practitioners worldwide are consistently encouraging. This is where honest peptide therapy lives - in the space between "proven beyond doubt" and "completely speculative." Neither extreme is accurate.
What I can control is the quality of care around the protocol. At IVgo, that means doctor consultations, blood work, pharmacy-compounded formulations, nurse-delivered pens, and ongoing support. The Wolverine Stack isn't a product I sell - it's a programme I administer. There's a difference.
If you're dealing with a stubborn injury, a slow surgical recovery, or chronic pain that's been running your life for longer than it should, let's have a conversation. The worst that happens is I tell you peptides aren't the right move for your situation. I promise you, that's a better outcome than buying mystery powder from the internet.
Book your Wolverine Stack consultation:
Call or WhatsApp 074 604 5555 | Visit ivgo.co.za | Instagram: @ivgo_cape_town
Chloé Nefdt is a SANC-registered Professional Nurse and the founder of IVgo, Cape Town's mobile IV therapy, NAD+ and peptide service. She has a particular interest in evidence-based peptide therapy and making advanced recovery protocols accessible - with proper medical oversight - outside the traditional clinic setting.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. BPC-157 and TB-500 are not approved therapeutic goods in South Africa or elsewhere. The research cited is predominantly preclinical (animal models), and human clinical data remains limited. Always consult a qualified healthcare professional before starting any new treatment. Athletes subject to WADA or SAIDS testing must not use BPC-157 or TB-500 - both are prohibited substances under current anti-doping regulations.